To further ascertain the effect of reduced CK1 activity on melanoma cell survival and proliferation we treated five different human melanoma cell lines with increasing doses of the CK1δ/CK1ε dominant inhibitors D4476 [19], PF670462 [20] or IC261 [21] and measured cell viability 72 h after treatment. Here, CSNK1A1 is linked to melanoma.